New perspectives for natural antimicrobial peptides: application as anti-inflammatory drugs in a murine model

Rosanna Capparelli1*, Francesco De Chiara1, Nunzia Nocerino1, Rosa Chiara Montella1, Marco Iannaccone1, Andrea Fulgione1, Alessandra Romanelli2, Concetta Avitabile2, Giuseppe Blaiotta3 and Federico Capuano4

Abstract
Background: Antimicrobial peptides (AMPs) are an ancient group of defense molecules. AMPs are widely distributed in nature (being present in mammals, birds, amphibians, insects, plants, and microorganisms). They display bactericidal as well as immunomodulatory properties. The aim of this study was to investigate the antimicrobial and anti-inflammatory activities of a combination of two AMPs (temporin B and the royal jellein I) against Staphylococcus epidermidis.

Results: The temporin B (TB-KK) and the royal jelleins I, II, III chemically modified at the C-terminal (RJI-C, RJII-C, RJIII-C), were tested for their activity against 10 different Staphylococcus epidermidis strains, alone and in combination. Of the three royal jelleins, RJI-C showed the highest activity. Moreover, the combination of RJI-C and TB-KK (MIX) displayed synergistic activity. In vitro, the MIX displayed low hemolytic activity, no NO2-production and the ability to curb the synthesis of the pro-inflammatory cytokines TNF-α and IFN-γ to the same extent as acetylsalicylic acid. In vivo, the MIX sterilized mice infected with Staphylococcus epidermidis in eleven days and inhibited the expression of genes encoding the prostaglandin-endoperoxide synthase 2 (COX-2) and CD64, two important parameters of inflammation.

Conclusion: The study shows that the MIX – a combination of two naturally occurring peptides - displays both antimicrobial and anti-inflammatory activities.

Background
Coagulase-negative staphylococci (CoNS) are highly abundant on the human skin, already a few hours after birth. The CoNS Staphylococcus epidermidis is an ubiquitous and permanent colonizer of human skin and the first cause of nosocomial infections [1]. Most infections with high morbidity and mortality are caused by methicillin-resistant strains of Staphylococcus epidermidis (MRSE) [2,3]. In addition, many MRSE strains form a capsule which favors biofilm development, where the pathogen can persist protected from antibiotics and invisible to the immune system [4,5].

New, unconventional antimicrobials are therefore urgently needed [6,7]. In this context, antimicrobial peptides (AMPs), in their natural form or after chemical modification, display interesting features as candidates to become new antimicrobials. They have a broad spectrum of activity against Gram-positive and Gram-negative bacteria, can be easily synthesized in laboratory and have limited toxicity for eukaryotic cells [8,9]. As innate immune components, AMPs lack specificity and immune memory, with the consequence that the pathogens rarely develop resistance to them [10]. Importantly, AMPs rapidly intercept and kill pathogens [11]. AMPs differ each other by size, sequence and secondary structure (α-helix or β-sheet) [12]. Most of them are hydrophobic and amphipathic [13]. AMPs can exert their activity by disrupting the membrane [14] or passing through the bacterial membrane [15]. Molecules belonging to the former class of AMPs permeabilize the membrane phospholipids bilayer and kill the bacterial cell; those belonging to the latter class pass through the bacterial membrane and

* Correspondence: capparel@unina.it
1 Faculty of Biotechnology, University of Naples “Federico II”, Naples 80134, Italy
Full list of author information is available at the end of the article

© 2012 Capparelli et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
interacts with variable intracellular components, much as traditional antibiotics. AMPs, in addition to the antimicrobial activity, display also immune-modulatory properties (such as chemotaxis, which contributes to bacterial elimination) and interact with natural and adaptive immunity [16,17]. Thus, in view of the above properties, AMPs represent one of the most promising future strategies for combating infections and microbial drug resistance. The present study describes two chemically modified AMPs - an analogue of the temporin B (TB-KK) secreted by the granular glands of the European red frog (Rana temporaria) [18] and an analogue of the royal jellein I (RJI-C) secreted by the mandible and hypopharyngeal glands of honeybees (Apis mellifera) [9,19]. These two peptides behave differently towards the bacterial membrane. RJI-C folds into beta sheets and aggregates onto the membrane; TB-KK folds into an alpha helix and does not aggregate onto the membrane [8,9].

Recent data demonstrate that hydrophobic peptides, when mixed with peptides possessing a net positive charge, give origin to a mixture with potential antibacterial activity [20,21]; second, that the combination of antimicrobial peptides derived from different organisms are highly active against Gram positive bacteria [9]. In agreement with these results, here we show that a mixture of TB-KK and RJI-C - two AMPs derived from different sources - displays strong antimicrobial activity against Gram-positive bacteria - modulates pro-inflammatory cytokines and nitric oxide production, in vitro and in vivo. The two peptides, following chemical modification, potentially can be made available in large quantities and in a homogeneous and highly pure form.

Results

Characterization of Staphylococcus epidermidis strains
To establish the clonal origin of the Staphylococcus epidermidis strains used in the study, the strains (10) were characterized phenotypically - with respect to their antibiotic resistance pattern and molecularly with respect to their Restriction Endonucleases Analysis (Pulse Field Gel Electrophoresis - REA-PFGE) pattern. All strains resulted resistant to aztreonam (30 μg; ATM30), bacitracin (10 μg; B2), cloxacillin (1 μg; CX1) and metronidazole (80 μg; M80) and sensitive to imipenem (10 μg; IPM10). The remaining 25 antibiotics displayed a strain specific pattern (Table 1). Also, with one exception (the strain SE), the strains displayed all different macro-restriction patterns, when analyzed by Sma I REA-PAGE (Figure 1). Thus, the strains used in this study belong to different clonal lineages.

In vitro antimicrobial activity of TB-KK and RJI-C
To evaluate the antimicrobial activity of RJI-C, RJI1-C, RJIII-C and TB-KK (Table 2) these AMPs were tested in vitro [8,9], individually and in combination, against 10 Staphylococcus epidermidis strains. Among the three royal jelleins, RJI-C showed the highest activity (MIC: 30 μg/ml) (Table 3). Tested in various combination (RJI-C at 20 μg/ml and RJI-C at 5–20 μg/ml; RJI-C at 20 μg/ml and RJIII-C at 5–20 μg/ml; RJI-C at 20 μg/ml and RJIII-C at 5–20 μg/ml), the royal jelleins did not display synergistic effects. Only RJI-C was thus tested for synergism with TB-KK. The combination of the two antimicrobials – RJI-C at 9 μg/ml and TB-KK at 6 μg/ml (MIX) – displayed a fractional inhibitory concentration index ≤ 0.5, which is evidence of synergism [20] (Table 3). The strains of Staphylococcus epidermidis were all sensitive to the MIX, but not its components (Table 4). This conclusion is supported by the larger inhibition ring of the MIX, compared to that of the individual components (Figure 2A).

Interestingly, the antibacterial activity of the MIX against probiotics bacteria (Lactobacillus plantarum, Lactobacillus Paracasei, Bifidobacterium animalis) was five-fold lower than that of gentamicin (Table 5).

In vitro hemolytic and cytotoxic activities of the MIX
To test the cytotoxic activity of the MIX, we used the hemolytic and the LC50 assays. The MIX lysed less than 12% of the murine erythrocytes (data not shown) and the LC50 value was 143,8 mg/ml versus 58.5 μg/ml of TB-KK and 64.6 μg/ml of RJI-C (Additional file 1: Table S1). The MIX was not toxic towards the macrophage J774 cells, which remained vital at 72 hours (Figure 2B).

In vitro the MIX does not induce synthesis of NO2
The MIX (RJI-C at 9 μg/ml and TB-KK at 6 μg/ml) did not induce NO2 synthesis in J774 cells. Rather, when these cells were stimulated with LPS (10 μg/ml/well for 3 hours) and then treated with the RJI-C, TB-KK and MIX reduced NO2 synthesis (Table 6), one of the parameters to determine the cellular toxicity.

In vitro anti-inflammatory activity of the MIX
To investigate whether the MIX, in addition to the antimicrobial activity, also displays anti-inflammatory activity, J774 cells (106 cells/well) were stimulated with either LPS or LTA (0.1, 1 or 10 μg/ml) for 3 hours. The results show that LPS stimulates inflammation in the J774 cells better than LTA (Figure 3A). Later, J774 cells were treated with gentamicin (5 μg/ml), acetylsalicylic acid (ASA, 5 μg/ml) or MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml) for 3 hours. In the absence of the agent causing inflammation (LPS), the MIX, gentamicin and ASA do not induce inflammation (Figure 3B). In J774 cells (106 cells/well) stimulated with LPS for 3 hours, the MIX curbs the synthesis of the pro-inflammatory cytokines TNF-α
Table 1 Results of antibiotic susceptibility tests of ten *Staphylococcus epidermidis* strains

| Strain | FD10 | P120 | AMK25 | AM10 | ATM30 | B2 | CB100 | CD30 | FOX30 | CAZ30 | A30 | CX1 | K15 | FF50 | GM10 | IPM10 | M80 | MZ75 | NET30 | FM300 | NB30 | T30 | P10 | PIP100 | RF30 | SP100 | RL100 | TE30 | VA30 |
|--------|------|------|-------|------|-------|----|-------|------|-------|-------|-----|-----|-----|------|------|------|-----|------|-------|-------|------|-----|-----|--------|-----|-------|------|-----|-----|
| S=     | R    | R    | R     | R    | R     | R  | I     | S    | I     | R     | S    | R    | S    | R     | R    | R    | R    | R     | R     | R    | R    | R      | R    | R     | R     | R    | R    |
| R=     | R    | R    | R     | R    | R     | R  | I     | S    | I     | R     | R    | R    | S    | R     | S    | R    | S    | R     | S    | R    | S    | R      | R    | R     | R     | R    | R    |
| S=     | R    | R    | R     | R    | R     | R  | I     | S    | I     | R     | S    | R    | S    | R     | S    | R    | S    | R     | S    | R    | S    | R      | R    | R     | R     | R    | R    |
| I=     | R    | R    | R     | R    | R     | R  | I     | S    | I     | R     | S    | R    | S    | R     | S    | R    | S    | R     | S    | R    | S    | R      | R    | R     | R     | R    | R    |
| R=     | R    | R    | R     | R    | R     | R  | I     | S    | I     | R     | S    | R    | S    | R     | S    | R    | S    | R     | S    | R    | S    | R      | R    | R     | R     | R    | R    |

R= strain resistant to the antibiotic.
S= strain sensitive to the antibiotic.
I= intermediate strains sensitive to the antibiotic.
and IFN-γ more efficiently than gentamicin and at the same extent of the ASA (Figure 3C).

These experiments demonstrate that the MIX exerts anti-inflammatory as well as antimicrobial activities, while the single components of the MIX have no anti-inflammatory activity (Additional file 2: Figure S1). Since COX-2 is a well-established parameter of inflammation [22], the J774 cells were stimulated with LPS (10 μg/ml) and 1 hour later treated with the MIX, RIJI-C (non-active peptide), acetylsalicylic acid (ASA), gentamicin or vehicle (PBS) for 3 hours. The level of the COX-2 protein was then detected by western blot. The MIX-treated cells, displayed a COX-2 protein level comparable to that of the cells treated with ASA or gentamicin, and much lower than that of the cells treated with RIJI-C or the vehicle (Figure 3D). The above results demonstrate that the MIX curbs inflammation to the same extent as ASA [23].

**In vivo anti-inflammatory activity of the MIX in mice stimulated with LPS**

To investigate further the property of the MIX to curb inflammation in vivo, LPS (250 μg, ~10 mg/Kg) was administrated to four groups of mice (3 mice/group). After 3 hours, the groups were treated respectively with the MIX (RIJI-C 9 μg/mouse + TB-KK 6 μg/mouse), gentamicin (5 μg in 100 μl/mouse) or ASA (5 μg in 100 μl/mouse). The last group received 100 μl of saline buffer as control. After 3 hours, the mice that received the MIX showed a reduced level of both the pro-inflammatory cytokines TNF-α and IFN-γ, when compared to gentamicin-treated group, but an higher expression level of IFN-γ, when compared to the ASA group (Figure 3E). In conclusion,

| Peptide  | Sequence         | Calc. mass (DA) | Meas. mass (DA) |
|----------|------------------|-----------------|-----------------|
| RIJI-C   | PFKIDHIHGYNH2    | 1230.46         | 1231.02         |
| RIJI-C   | TFKVISIHGGYNH2   | 1331.56         | 1331.90         |
| RIJI-C   | EFPKISIHGGYNH2   | 1359.57         | 1360.10         |
| TB       | YLLPVGNLKSSLNH2  | 1391.80         | 1391.20         |
| TB-KK    | KKYLLPIVGNLKLSSLNH2 | 2295.40       | 2294.30         |

**Table 2 Peptide sequences and mass analysis of the royal jelleins (RJ) and temporin (TB) used in the study**

**Figure 1** Sma I REA (Restriction Endonucleases Analysis)-PFGE patterns of Staphylococcus epidermidis strains: 1) 1Kb plus DNA Ladder (Invitrogen); 2) strain 5/25; 3) strain 9/1; 4) strain 2/2; 5) strain 10/28; 6) strain 12/14; 7) strain 5/8; 8) strain 12/26; 9) strain 5/6; 10) strain SE (untypable); 11) strain 3/28; 12) Lambda DNA - Hind III Digested (Invitrogen); 13) DNA Size Standards - Lambda Ladder (Bio-Rad); 14) PFGE marker, 0.225–2.2 Mb S. cerevisiae chromosomal DNA (Bio-Rad).
In vivo antimicrobial efficacy of the MIX given intravenously at 12 hours post infection

To evaluate the efficacy of the MIX to contrast microbial infection, four groups of mice (15 mice/group) were infected with lethal dose (10⁸ CFU/mouse) of Staphylococcus epidermidis (SE). This strain was chosen since it is resistant to the majority of the antibiotics tested (Table 1).

One group did not receive any treatment (control group); a second group received sterile PBS (100 μl/mouse) (placebo group – data not shown); the third group received the MIX (RJI-C 9 μg/mouse + TB-KK 6 μg/mouse); the fourth group received gentamicin (5 μg/mouse). PBS, MIX and gentamicin were administered intravenously at 3 hours post infection. In both, placebo and control groups, the bacterial load of kidneys and spleens increased progressively, while it decreased in the groups treated with gentamicin or the MIX (Additional file 3: Figure S2). Upon treatment of the mice with the MIX, the acute phase proteins, which represent important markers of inflammation [24], were evaluated (Additional file 4: Table S2). The SAA (Serum amyloid A), haptoglobin and fibrinogen were within normal ranges in the mice treated with the MIX or with gentamicin, while significantly high in the control mice (infected but not treated) (Additional file 4: Table S2).

Table 3 The FIC index against Staphylococcus epidermidis strains: ≤0.5, synergy ; >0.5, no interaction

| Antimicrobial peptides | MIC<sub>100</sub> | Fic index |
|------------------------|------------------|-----------|
| RJI-C                  | 30 μg/ml (24 μM) |
| RJI-C                  | 200 μg/ml (150 μM) |
| RJI-C                  | 300 μg/ml (220 μM) |
| TB-KK                  | 7 μg/ml (3 μM)   |
| Gentamicin             | 5 μg/ml (10 μM)  |
| RJI-C + TB-KK          | 9 μg/ml + 6 μg/ml (7.3 μM + 2.6 μM) | 0.5 |

Table 4 Antimicrobial activity of the MIX and its components against different strains of Staphylococcus epidermidis

| Strains   | % inhibition of bacterial growth RJI-C 9 μg/ml (7.3 μM) | % inhibition of bacterial growth TB-KK 6 μg/ml (2.6 μM) | % inhibition of bacterial growth RJI-C 9 μg/ml + TB-KK 6 μg/ml (RJI-C 7.3 μM + TB-KK 2.6 μM) (MIX) |
|-----------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| 3/28      | 17 ± 2                                                 | 19 ± 2                                                 | 91 ± 1                                                                                           |
| 2/2       | 18 ± 1                                                 | 23 ± 0.5                                               | 96 ± 2                                                                                           |
| 5/6       | 4 ± 3                                                  | 10 ± 1                                                 | 100 ± 0                                                                                          |
| 5/8       | 12 ± 2                                                 | 21 ± 2                                                 | 95 ± 2                                                                                           |
| 12/14     | 11 ± 0.5                                               | 20 ± 3                                                 | 92 ± 1                                                                                           |
| 9/1       | 18 ± 0                                                 | 26 ± 2                                                 | 96 ± 2                                                                                           |
| 10/28     | 0                                                      | 4 ± 1                                                  | 100 ± 0                                                                                          |
| 12/26     | 19 ± 2                                                 | 14 ± 2                                                 | 100 ± 0                                                                                          |
| 5/25      | 15 ± 1                                                 | 21 ± 1                                                 | 90 ± 2                                                                                           |
convoluted tubules, less glomerular hyperplasia, and no lymphocyte infiltration (Figure 6 panel 2–4).

In vivo antimicrobial efficacy of the MIX for the period of 12 days
To test the antimicrobial activity of the MIX in vivo for a longer period, mice were infected with a sub-lethal dose (10⁷ CFU/mouse) of Staphylococcus epidermidis and then treated with the MIX. Four groups of mice (24 mice/group) were infected with the bacterial strain (SE). One group of mice did not receive any treatment (control group); a second group received sterile PBS (100 μl/mouse) (placebo group); the third group received the MIX (RJI-C: 9 μg/mouse + TB-KK: 6 μg/mouse); the fourth group received gentamicin (5 μg/mouse). PBS, MIX and gentamicin were administered intravenously in three boosts 3, 6 and 9 days post infection. In the placebo and the control groups, the bacterial load of kidneys and spleens (the target organs of the pathogen) increased progressively, while the load was significantly lower in the groups treated with gentamicin or the MIX. Eleven days after the infection, the mice treated with gentamicin were still infected, while those treated with the MIX were already sterile (Figure 7A-B).

Four days after the infection, in addition to spleen and kidneys (10⁶ CFU/gr and 10⁷ CFU/gr respectively), the bacterium was also detected (at a threshold level: 10² CFU/g) in the liver (data not shown). Thus, the MIX is slightly more effective than gentamicin (Figure 7A-B). In all four groups, bacteria were no longer detected in the blood circulation within 2 h from infection (Additional file 5: Figure S3).

In vivo anti-inflammatory efficacy of the MIX for the period of 12 days
To evaluate the anti-inflammatory activity of the MIX, the expression levels of the TNF-α, IFN-γ, IL-10 cytokines genes were measured in the kidneys. The experiment was carried out on the same four groups of mice described in the previous paragraph. For this purpose, the expression levels of the cytokines were measured 24 and 48 hours after each treatment with MIX (or 4, 5, 7, 8,10 and 11 days post infection). In the group treated with the MIX, compared to the group treated with gentamicin, the TNF-α and IFN-γ levels were under expressed (at 7 days) while the IL-10 levels were over expressed (at 10 days) (Figure 7C). This result suggests that the MIX controls inflammation better than gentamicin.

Discussion
Recently we demonstrated that new antimicrobials are more effective than traditional antibiotics against Staphylococcus epidermidis [25,26]. The present study extends these results, providing evidence that the MIX – a mixture of a royal jellin modified at the C-terminal (RJI-C) and an analogue of temporin B (TB-KK) – is a valid alternative to the use of gentamicin against skin infections caused by Staphylococcus epidermidis.

In vivo, endogenous antimicrobial peptides (such as human defensins and cathelicidins) are known to be pleiotropic: they act as antimicrobials [27]; neutralize...
bacterial components (LTA and LPS), which otherwise would induce an excess of inflammation and tissue damage [28,29]; attract inflammatory cells to the wound site and promote wound healing.

The two exogenous components of the MIX also behave in a pleiotropic fashion: they control the bacterial load (Figure 7A-B and Additional file 3: Figure S2), inhibit the synthesis of pro-inflammatory cytokines (Figures 4 and 7C) and control the expression of COX-2 (Figures 3D and 5B), the acute phase proteins (Additional file 4: Table S2) and the expression of the CD64 receptor (Figure 5A). At the histological level, the MIX reduces kidney lymphocyte infiltration (Figure 6).

Mice infected with a sub-lethal dose of Staphylococcus epidermidis and three days later treated with the MIX (RJI-C: 9 μg/mouse + TB-KK: 6 μg/mouse), within 11 days from treatment, displayed sterile kidneys and spleen – the organs targeted by the bacterial strain used in this study (Figure 7A-B). Samples collected at 15 min intervals from infection showed that bacteria leave the blood circulation within 2 h (Additional file 5: Figure S3). These results are clinically relevant since they suggest that the MIX can potentially be used in humans, where infection is generally caused by a small initial inoculum and treatment is therefore initiated several days after infection (Figure 7A-B).

The MIX is not toxic for eukaryotic cells, in vitro and in vivo (Figure 2B); its components act synergistically (Figure 2A) and becomes moderately hemolytic (12%). In addition, the MIX reduces the synthesis of NO2 in cells infected with Staphylococcus epidermidis (Table 6). These additional properties make the MIX a candidate for a new generation drug.

In vitro and in vivo experiments demonstrate that the MIX down regulates the level of the pro-inflammatory cytokines TNF-α and IFN-γ while enhancing the expression of the anti-inflammatory cytokine IL-10. This effect is comparable to that of gentamicin, a well-known antimicrobial drug. These results confirm that the MIX, in addition to an antibacterial activity, also exerts - in vivo and in vitro - an anti-inflammatory activity.

The intestinal flora represents a defense barrier against pathogens [30]. We therefore also investigated whether the MIX spared probiotic bacterial species in vitro. While gentamicin killed the totality of the probiotics tested (Lactobacillus plantarum, Lactobacillus Paracasei, Bifidus animalis), the MIX killed a minority of each bacterial species (29%-23%-25%, respectively) (Table 5).

The influence of the MIX on the major cell signaling pathways was also studied. CD64 and COX-2 warn about the cell exposure to inflammatory stimuli [31,32]. The MIX reduced the expression level of COX-2 (Figures 3D and 5B) and CD64 (Figure 5A), proving that the MIX exerts also anti-inflammatory activity. The CD64 levels are high in the mice infected. In the mice infected and then treated with MIX at both 3, 6 and 9 hours from treatment, levels of CD64 are reduced (Figure 5A). This last result provides evidence that the MIX has effects on mechanisms of both innate and adaptive immunity.

Conclusions
This study provided evidence which suggests an analogy between endogenous AMP and the MIX, consisting of exogenous and chemically modified AMPs. Both display a two-fold role, rapidly recognizing the presence of a pathogen and preventing an excess of inflammation.

Methods
Bacteria
List and origin of Staphylococcus epidermidis used in this study is reported in Additional file 6: Table S3. All strains were isolated from patients hospitalized at the Medical School of the University of Naples Federico II. All strains were molecular identified by means of kat
A-RFLP analysis technique described by Blaiotta et al. [33]. The study does not investigate clinical aspects of the disease, nor it uses human specimen. The study therefore does not require the Ethic Committee approval.

Antibiotic susceptibility of Staphylococcus epidermidis strains

The antibiotic-susceptibility profile of strains was tested using the disk diffusion method on Mueller-Hinton agar, according to the NCCLS guidelines (2002) [34]. The antibiotics used and their concentrations were as follows: amoxicillin (25 μg; AMX25), ampicillin (10 μg; AM10), aztreonam (30 μg; ATM30), bacitracin (10 μg; B2), carbenicillin (100 μg; CB100), ceftazidime (30 μg; CAZ30), cefoxitin (30 μg; FOX30), cephaloridine (30 μg; CD30), cloxacillin (1 μg; CX1), erythromycin (15 μg; E15), fosfomycin (50 μg; FF50), fusidic acid (10 μg; FD10), gentamicin (10 μg; GM10), imipenem (10 μg; IPM10), lincomycin (2 μg; MY2), metronidazole (80 μg; M80), mezlocillin (75 μg; MZ75), netilmicin (30 μg; NET30), nitrofurantoin (300 μg; FM300), novobiocin (30 μg; NB30), oxytetracycline (30 μg; T30), penicillin-G (10 μg; P10), piperacillin (100 μg; PIP100), rifampicin (30 μg; RF30), chlorotetracycline (30 μg; A30), spiramycin (100 μg; SP100), sulfamethoxazole (100 μg; SP100), tetracycline (30 μg; TE300), and vancomycin (30 μg; VA30). All antibiotics were provided by BioMérieux SA, (Marcy l’Etoile, France).

Pulsed-field electrophoresis of Staphylococcus epidermidis strains

The procedure adopted was that described [35]. Briefly, inserts of intact DNA were digested in 200 μl of appropriate buffer supplemented with 40 U of Sma I (Promega, Milan). Pulsed field gel electrophoresis (PFGE) of the restriction digests was performed by using the CHEF system (Bio-Rad Laboratories, Hercules, CA, USA) with 1% (wt/vol) agarose gels and 0.5 x TBE as running buffer, at 10°C. Restriction fragments were resolved in a single run, at constant voltage of 6 V cm⁻¹ and an orientation angle of 120° between electric fields, by a single phase procedure for 24 h with a pulse ramping between 1 and 50s.
Antibacterial activity of AMPs

Antibacterial activity of the peptides used in this work was evaluated as described previously [8]. A potential synergism (FIC) between TB-KK and RJI-C (MIX) was evaluated by adding combinations of two peptides in a serial two-fold dilutions (RJI-C 5–100 μg, 40 μl/well; TB-KK 5–100 μg, 40 μl/well) to wells containing 10^5 CFU/well in 60 μl [8]. The fractional inhibitory concentration (FIC) index for combinations of two peptides was calculated according to the equation: FIC index = FICA + FICB = A/MICA + B/MICB, where A and B are the MICs of drug A and drug B in the combination, MICA and MICB are the MICs of drug A and drug B alone, and FICA and FICB are the FICs of drug A and drug B. The FIC indices were interpreted as follows: ≤0.5, synergy; 0.51–4.0, no interaction; > 4.0, antagonism [23].

The growth inhibition percentages of Staphylococcus epidermidis and probiotic strains were assessed under the same conditions.

Inhibition zone assay and test of the haemolytic activity of the antimicrobials
The MIX (RJI-C at 9 μg/ml and TB-KK at 6 μg/ml) was tested for its haemolytic activity using mouse red blood cells and for inhibition zone assay test [8]. The MIX was tested for its haemolytic activity using mouse red blood cells. The blood was collected from the tail of the animals and centrifuged (4x10^5 g for 3 min). The erythrocytes were washed with saline, suspended at 3x10^6 erythrocytes/ml, mixed with the peptide combination (RJI-C 9 μg and TB-KK 6 μg in 100 μl saline) and incubated for 1 h at 37°C. The haemolytic activity was measured according to the formula OD_peptide - OD_negative control / OD_positive control - OD_negative control X 100 where the negative control (0% haemolysis) was represented by erythrocytes suspended in saline and the positive control (100% haemolysis) was represented by the erythrocytes lysed with 1% triton X100 [36].

The LC50 values relative to the two peptides and the MIX were calculated as described [37].

Cell culture
J774 murine macrophages from the American Tissue Culture Collection (ATCC, Rockville, MD, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Cambrex Bio Science, Verviers, Belgium). Culture media contained 10% fetal bovine serum (FBS, Sigma, Milan, Italy), 100 IU/ml penicillin, 100 μg/ml streptomycin (all from Gibco, Paisley, Scotland). Cells were seeded on 96-well plates (Falcon, Milan) for the MTT Assay, and on 24-well plates (Falcon, Milan) for NO_2 measurements, fluorescence microscopy analysis, and RT-PCR assays. Cell monolayers were grown to adherence before the experiments were started.

Mice
Experiments were carried out on female BALB/c mice (aged 8 to 10 weeks) at the animal facility of the University of Naples. Bacteria (10^7 or 10^8 CFU/mouse) were inoculated by intravenous routes (i.v.). LPS (250 μg, ~10 mg/Kg) (Sigma-Aldrich Milan), or an equivalent volume of sterile 0.9% saline vehicle (250 μl) was administered intraperitoneally. Blood samples were drawn from the tail vein using 0.5 ml syringes. Spleen and kidney were collected at several time points (4, 5, 7, 8, 10, 11 and 12 days) after the mice infection with a sub-lethal dose of Staphylococcus epidermidis (10^7 CFU/mouse). However the same organs were also collected at 3, 6, 9...
and 12 hours after infection with a lethal dose of *Staphylococcus epidermidis* (10⁸ CFU/mouse). Spleens and kidneys were dissected and weighed. One g of each sample was homogenized in 1 ml saline and serially diluted in saline.

Colony forming units (CFU) were evaluated by the plate count assay. Animal experiments were approved by the Animal Care Committee of the University of Naples.

**Measurement of cell viability**

Analysis of cell viability was performed using the CellTiter 96® AQueous One Solution Cell Proliferation Assay system (MTS assay) (Promega, Madison, WI, USA). J774 cells were seeded at 2500 cells per well in a 96-well plate and incubated at 37°C, in a humidified atmosphere with 5% CO₂. TB-KK 15 µg/ml, RJI-C 15 µg/ml, MIX (TB-KK 6 µg/ml + RJI-C 9 µg/ml) or RJI-C (Control 15 µg/ml) were added to the medium immediately after cell adhesion. At each time point 20 µl of CellTiter 96® AQueous One Solution reagent was added to each well, according to the manufacturer’s instructions. Absorbance was recorded at 490 nm after 2 h using an EnVision 2102 multilabel reader (PerkinElmer, Waltham, USA).

Nitrite formation in J774 cells stimulated with LPS and treated with RJI-C, TB-KK, and the MIX

Nitrite accumulation (NO₂⁻, µmol/10⁶ cells) in the cell culture medium was determined by the Griess reaction [38].
Western Blot Analysis COX-2
Cell lysates for Western blotting were prepared by washing cells twice with ice-cold phosphate-buffered saline followed by cell lysis in 500 μl of Fastprep lysis buffer (1X protease inhibitor cocktail tablet (Roche EDTA free) resuspended in 1X PBS) on ice and lysed 20s at 6.5 intensity, 2X interralling with 5–10 minutes on ice. Cell lysates were centrifuged for 10 min at 7800 g at 4°C, and the supernatants were collected and stored at −80°C until analysis. Lysate protein concentrations were measured using the Bio-Rad protein assay method, as described in the manufacturer’s instructions. Cell lystate volumes corresponding to 20 μg of total protein were diluted 1:1 in Laemmli buffer (Bio-Rad) and boiled for 5 min prior to electrophoresis on a 10% acrylamide gel. The resolved proteins were electroblotted on PVDF membrane (Bio-Rad) by the Bio-Rad semidy transfer method, according to the manufacturer’s instructions. Membranes were stained with Ponceauroxid to verify uniform protein transfer, and then blocked with blocking buffer (1X TBS, 0.1% Tween-20, 5% w/v non-fat dry milk) for 1 h at RT. Blocked membranes were incubated overnight at 4°C with COX-2 mouse monoclonal antibody (diluted 1/2000), β-actin mouse monoclonal antibody (diluted 1/10,000). Blots were washed three times in TBS-Tween before incubation with the appropriate horseradish peroxidase-conjugated secondary antibody (sheep antimouse IgG diluted 1/5000) for 1 h at room temperature.

After three washes with TBS-Tween, the signal was developed using standard procedure. Gel image was acquired in Fujifilm LAS-3000 Chemiluminescence system (Fujifilm Life science).

Real time PCR of pro-inflammatory
Total RNA was isolated from the tissue and the cell line after treatment by using Trizol reagent (Invitrogen, Milan, Italy). RNA was suspended in RNase-DNase free distilled water, assessed for concentration (by measuring the absorbance at 260 nm) and purity (by ascertaining that the A260/A280 ratio was >1.9). RNA (1 μg) was then treated with 1U RNase-free DNase (Promega, Madison, WI). DNA contamination of RNA samples was excluded by PCR with primers specific for the gapdh gene. Reverse transcription was carried out with ImProm-II reverse transcriptase (Promega, Madison, WI) and oligo (dT). Real-time PCR was performed on 50 ng cDNA, using 1x master mix SYBRGreen (Applied Biosystem, Milan) in a StepOne Applied Biosystem instrument (Applied Biosystem, Milan). Reactions were performed in 20 μl in triplicate. The primer list is reported in Additional file 7: Table S4.

ELISA test of pro-inflammatory cytokines
In addition, the ELISA test was used to measure the anti-inflammatory activity of the MIX and its components: RJI-C 9 μg/mL e TB-KK 6 μg/mL.

Briefly, J774 cells (10⁶ cells/well) were stimulated with LPS (10 μg/ml; 1 hour), treated with RJI-C 9 μg/ml or TB-KK 6 μg/ml or MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml) in presence or absence of LPS (10 μg/ml). The supernatants from these cells (100 μl/well) were transferred into the wells of a plate previously coated with mouse anti-human TNF-α (BD Pharmingen; 50 μl diluted 2 x 10-3/well) or mouse anti-human IFN-γ (Biosciences, 50 μl diluted 2 x 10-3/well) along with a second dose of anti IFN-γ or TNF-α, HRP-labelled rabbit anti mouse IgG diluted 10⁻³ (100 μl/well) and TMB peroxidase
substrate (BIORAD; 100 μL/well), in the order. The optical density of each well was read at 405 nm using a microplate reader (Bio-Rad, Japan). Triplicate positive and negative controls were included in each plate [39].

**Cytofluorimetric analysis**

CD64 expression in total White Blood Cells was analyzed using a Flow cytometry EPICS Elite (Beckman Coulter, Fullerton, CA). Daily instrument quality control including fluorescence standardization, linearity assessment, and spectral compensation were performed to ensure identical operation from day to day. At least 10,000 events for each sample was analyzed and the data were saved for later analysis on EXPO32 software (Beckman Coulter). Data analysis was performed by using electronic gating on the basis of FSC and SSC excluded

**Figure 7** (A-B) Bacterial load in spleen and kidneys of animals (24/groups) infected with Staphylococcus epidermidis (10^7 CFU/mouse; rumble line); infected with Staphylococcus epidermidis (10^7 CFU/mouse) and treated with the MIX (RJI-C at 9 μg/mouse and TB-KK at 6 μg/mouse; square line) or gentamicin (5 μg/mouse; triangle line) *p <0.05, **p < 0.01; ***p < 0.001, Student’s t test gentamicin vs MIX. (C) TNF-α, IFN-γ, IL-10 mRNA expression levels were quantified, at the indicated time points, in mice infected with Staphylococcus epidermidis (10^7 CFU/mouse) or infected with Staphylococcus epidermidis (10^7 CFU/mouse) or treated with three different doses (I,II,III) of the MIX (RJI-C at 9 μg in 100 μl/mouse and TB-KK at 6 μg in 100 μl/mouse) or gentamicin (5 μg in 100 μl/mouse). Values were normalized with GAPDH and compared to untreated control. *p <0.05, **p < 0.01; ***p < 0.001, Student’s t test gentamicin vs MIX.
cellular debris and nonviable cells. PE-conjugated anti-mouse CD64 expression was measured using a log_{10} scale. Briefly, 50 ul of whole blood was incubated for 10 minutes at room temperature with saturating amounts of phycoerytrine-conjugated anti-CD64 murine monoclonal antibody (Becton Dickinson) followed by red blood cell lysis with an ammonium chloride-based red cell lysis solution (Beckman Coulter, Fullerton, CA). Samples were then washed once and resuspended with phosphate-buffered saline at pH 7.4, to a volume of 1 mL.

Other methods
The kidney was fixed in 10% buffered formalin, sectioned (10 μm) and stained with hematoxylin-eosin according to standard protocols. Bacterial counts and cytokine levels were analyzed using Student’s t test.

Additional files

Additional file 1: Table S1. Lethal concentration (LC_{50}) of Temporin B –KK, Royal jelleins-IC, MIX through their hemolytic activity on mouse erythrocytes.

Additional file 2: Figure S1. Anti-inflammatory activity. The levels of IFN-γ and TNF-α were determined by a sandwich ELISA test in J774 cells untreated, J774 cells infected with S. epidermidis for 1 h; J774 cells stimulated with RJI-C (9 μg/ml) for 1 h; J774 cells stimulated with TB-KK (6 μg/ml) for 1 h; J774 cells stimulated with MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml) for 1 h; J774 cells infected with S. epidermidis for 1 h and stimulated with MIX for 1 h. Results from two representative experiments are presented as mean value ± S.D. *P < 0.05, **P < 0.01; ***P < 0.001, Student’s t test. S. epidermidis vs S. epidermidis + MIX.

Additional file 3: Figure S2 (A-B). Bacterial load in spleen and kidneys of S. epidermidis infected mice (rumble line) and subsequently treated with the MIX (square line) or gentamicin. Data are representative of 15 animals/group. Student’s t test gentamicin vs MIX not significant.

Additional file 4: Table S2. Anti-inflammatory activity. The levels of IFN-γ and TNF-α were determined by a sandwich ELISA test in J774 cells untreated, J774 cells infected with S. epidermidis for 1 h; J774 cells stimulated with RJI-C (9 μg/ml) for 1 h; J774 cells stimulated with TB-KK (6 μg/ml) for 1 h; J774 cells stimulated with MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml) for 1 h; J774 cells infected with S. epidermidis for 1 h and stimulated with MIX for 1 h. Results from two representative experiments are presented as mean value ± S.D. *P < 0.05, **P < 0.01; ***P < 0.001, Student’s t test. S. epidermidis vs S. epidermidis + MIX.

Additional file 5: Figure S3. Time course (30, 60, 90 and 120 minutes) of bacterial load in blood of S. epidermidis infected mice.

Additional file 6: Table S3. Origin of S. epidermidis strains.

Additional file 7: Table S4. Sequences of the primers.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
RC designed the study and wrote the paper. AR and CA designed and synthesized the peptides. GB carried out the antibiotic resistance test. NN, RCM and MI carried out cell culture and in vivo tests. FDC, AF and FC carried out biochemical, statistical and in vivo tests. All authors read and approved the final manuscript.

Acknowledgements
This study was supported with funds from the Ricerca Finalizzata 2009 (RF-2009-1539461).

Author details
1Faculty of Biotechnology, University of Naples “Federico II”, Naples 80134, Italy. 2Department of Biological Sciences, University of Naples “Federico II”, Naples 80134, Italy. 3Department of Food Science, University of Naples “Federico II”, Portici 80055, Italy. 4Department of Food Inspection IZ5 ME, via Salute 2, Portici 80055, Italy.

Received: 30 July 2012 Accepted: 12 November 2012

References
1. Uckay I, Pittet D, Vaudaux P, Sax H, Lew D, Waldvogel F: Foreign body infections due to Staphylococcus epidermidis. Ann Med 2009, 41:109–119.
2. Neely AN, Maley MP: Survival of enterococci and staphylococci on hospital fabrics and plastic. J Clin Microbiol 2000, 38:724–726.
3. Jamaluddin TZ, Kusuhara-Arai K, Hisata K, Terasawa M, Cui L, Baba T, Sotozono C, Kinoshita S, Ito T, Hiramatsu K: Extreme genetic diversity of meticillin-resistant Staphylococcus epidermidis strains disseminated among healthy Japanese children. J Clin Microbiol 2008, 46:3778–3783.
4. Fitzpatrick F, Humphreys H, O’Connor JP: The genetics of staphylococcal biofilm formation will a greater understanding of pathogenesis lead to better management of device-related infection? Clin Microbiol Infect 2005, 11:967–973.
5. Folliksøn A, Haagensen JA, Zampaloni C, Sternberg C, Molin S: Biofilm induced tolerance towards antimicrobial peptides. PLoS One 2008, 3(4):e1891. Apr 2.
6. Levy SB, Marshall B: Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004, 10:212–219.
7. Brogden NR, Brogden KA: Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? Int J Antimicrob Agents 2011, 38(3):217–225. Sep.
8. Capparelli R, Romanelli A, Iannaccone M, Nicerino N, Ripa R, Pensato S, Pedone C, Ianneli D: Synergistic antibacterial and anti-inflammatory activity of temporin A and modified temporin B in vivo. PLoS One 2009, 4(7):e191.
9. Romanelli A, Moggio L, Montella RC, Campiglia P, Iannaccone M, Capuano F, Pedone C, Capparelli R: Peptides from Royal Jely: studies on the antimicrobial activity of jelleins, jelleins analogs and synergy with temporins. J Pept Sci 2011, 17:348–352.
10. Peschel A, Sahl HG: The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 2006, 4(7):529–536. Jul.
11. Born HG: Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 1995, 13:81–92.
12. Marshall SH, Arenas G: Antimicrobial peptides: A natural chemical antibiotics and a potential for applied biotechnology. Electron J Biotechnol 2003, 6:271–284.
13. Yount NY, Bayer AS, Xiong YQ, Yeaman MR: Advances in antimicrobial peptide immunobiology. Biopolymers 2006, 84(5):435–458.
14. Powers JP, Hancock RE: The relationship between peptide structure and antibacterial activity. Peptides 2003, 24(11):1681–1691. Nov.
15. Hancock RE, Rozeck A: Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol Lett 2002, 206(2):143–149. Jan 10.
16. Ganz T: The role of antimicrobial peptides in innate immunity. Integ Comp Biol 2003, 43(2):300–304. Apr.
17. Steintraesser L, Kraneburg U, Jacobson F, Al-Renna S: Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology 2011, 216:322–333.
18. Simmaco M, Mignogna G, Canofeni S, Miele R, Mangoni ML, Barra D: Temporins, antimicrobial peptides from the European red frog Rana temporaria. Eur J Biochem 1996, 242:788–792.
19. Fontana R, Mendes MA, de Souza BM, Konno K, César LM, Malaspina O, Palma MS: Jelleins: a family of antimicrobial peptides from the Royal Jely of honeybees (Apis mellifera). Peptides 2004, 25(6):919–928. Jun.
20. Rosenfeld Y, Barra D, Simmaco M, Shai Y, Mangoni ML: A synergism between temporins toward Gram-negative bacteria overcomes resistance imposed by the lipoplysaccharide protective layer. J Biol Chem 2006, 281(39):28665–28674.
21. Mangoni ML, Epand RF, Rosenfeld Y, Peleg A, Barra D, Epand RM, Shai Y: Lipopolysaccharide, a key molecule involved in the synergism between temporins in inhibiting bacterial growth and in endotoxin neutralization. J Biol Chem 2008, 283(34):22907–22917.
22. Selbert K, Masferrier JL: Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994, 4(1):17–23.
23. Chávez E, Castro-Sánchez L, Shibayama M, Tsutsumi V, Pérez Salazar E, Moreno MG, Muriel P: Effects of acetyl salicylic acid and ibuprofen in chronic liver damage induced by CCH4. J Appl Toxicol 2012, 32(1):51–59. Jan.

24. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D: LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation 2010, 7:47–56.

25. Capparelli R, Ventimiglia I, Palumbo D, Nicodemo D, Salvatore P, Amoroso MG, Iannaccone M: Expression of recombinant puroindolines for the treatment of staphylococcal skin infections (acne vulgaris). J Biotechnol 2007, 128(3):606–614. Feb 20.

26. Kang M-S, Oh J-S, Lee S-W, Lim H-S, Choi N-K, Kim S-M: Interferon- γ, interleukin-1 and tumor necrosis factor-α synthesis during experimental murine staphylococcal infection. J Nutr Metab 2012, 2012:61.

27. Lai Y, Gallo RL: AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009, 30:131–141.

28. Lee SH, Baek DH: Antibacterial and neutralizing effect of human β-defensins on Enterococcus faecalis and Enterococcus faecalis lipoteichoic acid. J Endod 2012, 38(3):351–356. Mar.

29. Suzuki K, Murakami T, Kawai-Arai K, Tamura H, Hiramatsu K, Nagaoka I: Human anti-microbial cathelicidin peptide LL-37 suppresses the LPS-induced apoptosis of endothelial cells. Int Immunol 2011, 23(3):185–193. Mar.

30. Northagen GE, Engstrom PE, Hammarstrom L, Smith CJ, Nord CE: Oral and intestinal microflora in individuals with different immunoglobulin deficiencies. Eur J Clin Microbiol Infect Dis 1990, 9:631–633.

31. Nieminen R, Lahti A, Jalonen U, Kankaanranta H, Moilanen E: Monitoring lactic acid bacteria strains during “cacioricotta” cheese production by restriction endonucleases analysis and pulsed-field gel electrophoresis. J Dairy Sci 2001, 84:139–144.

32. Orsine JVC, da Costa RV, da Silva RC, de Fátima Menezes Almeida Santos M, Novaes MRCG: Isocryptomerin, a novel membrane-active antifungal compound from Selaginella tamariscina. Biochem Biophys Res Commun 2009, 379(3):676–680. Feb 13.

33. Orsine JVC, da Costa RV, da Silva RC, de Fátima Menezes Almeida Santos M, Novaes MRCG: Antifungal compound from Selaginella tamariscina. Biochem Biophys Res Commun 2009, 379(3):676–680. Feb 13.

34. NCCLS: Performance Standards for Antimicrobial Susceptibility; Seventeenth Informational Supplement. Wayne, PA: NCCLS; 2002. NCCLS document M100-S17.

35. Blaiotta G, Moschetti G, Simeoli E, Andolfi R, Villani F, Coppola S: Diversity of Staphylococcus sp. strains based on partial kat (catalase) gene sequences and design of a PCR-RFLP assay for identification and differentiation of coagulase positive species (S. aureus, S. delphini, S. hyicus, S. intermedius, S. pseudintermedius, and S. schleiferi subsp. coagulans). J Clin Microbiol 2010, 48:192–201.

36. Rozalska B, Wadstrom T: Interferon-γ, interleukin-1 and tumor necrosis factor-α synthesis during experimental murine staphylococcal infection. FEMS Immunol Med Microbiol 1993, 7:145–152.